MSD-001, "AI-derived psychedelic"

I've been seeing this in my news feed lately, perhaps some of you may be interested in it. As the government becomes more accepting of therapeutic psychedelics, and with the FDA approving their use in clinical trials, companies are now interested in making new designer psychedelics.

Using AI tools, and 5-MeO-MiPT as a base molecule, Mindstate Design Labs is seeking to fine-tune psychedelic experiences, with less serotonin "noise" caused by the somewhat unpredictable receptor affinities of Shulgin's typtamines, and their natural occuring cousins. This article is from last year, but the MSD-001 product is again in the news, because it's now in the clinical trial phase.

Mindstate Uses AI to Design “Next-Gen” Psychedelics Combined With 5-MeO-MiPT - Lucid News